No Data
Tonghe Pharmaceutical: First Quarter Report 2025
Tonghe Pharmaceutical: Annual Report 2024
Tonghe Pharmaceutical: 2024 Annual Report Summary
Jiangxi Synergy Pharmaceutical (300636.SZ): In the first quarter, the net income was 20.7814 million yuan, a year-on-year decrease of 52.30%.
Gelonghui, April 24丨Jiangxi Synergy Pharmaceutical (300636.SZ) announced its Q1 2025 report, with revenue of 0.187 billion yuan, a year-on-year decrease of 9.47%; net income attributable to shareholders of the listed company was 20.7814 million yuan, down 52.30% year-on-year; net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 17.6806 million yuan, down 56.33% year-on-year; basic EPS was 0.0495 yuan.
Jiangxi Synergy Pharmaceutical (300636.SZ): The product of Amlodipine Besylate has obtained the pharmaceutical registration certificate from South Korea.
Gelonghui, April 15 - Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received the Pharmaceutical registration certificate for Amiasartan potassium issued by the Ministry of Food and Drug Safety of South Korea. Amiasartan potassium is suitable for the treatment of primary hypertension in adults.
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
